Physician profile
Mark Steven Grajcar
NPI 1669416137
$3,390.12
in general payments reported to CMS, 2019-2025
35 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $451 · 2021: $514 · 2022: $627 · 2023: $600 · 2024: $697 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $407.59 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.52 | 2019-2024 | Jardiance, Tradjenta |
| Novo Nordisk INC | $260.00 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $249.10 | 2019-2024 | |
| Corcept Therapeutics | $190.76 | 2022-2025 | Korlym |
| Lilly USA, LLC | $151.82 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $103.11 | 2019-2024 | Arexvy, Shingrix |
| Arbor Pharmaceuticals, INC. | $95.12 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $94.18 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.80 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $81.79 | 2019-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Allergan, INC. | $65.67 | 2020-2022 | |
| Amgen INC. | $46.52 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.49 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.17 | 2020-2021 | |
| Corium, LLC | $42.79 | 2022-2023 | Azstarys |
| Horizon Therapeutics Plc | $37.61 | 2019-2022 | |
| Organon LLC | $31.81 | 2022 | |
| Mylan Specialty L.P. | $29.32 | 2020-2022 | |
| Eisai INC. | $28.16 | 2021 | |
| Stryker Corporation | $23.73 | 2024 | Mako |
| Qol Medical, LLC | $22.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.95 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.91 | 2023 | Amvuttra |
| Exact Sciences Corporation | $21.50 | 2024 | Cologuard Collection Kit |
| Recor Medical INC | $21.11 | 2024 | Paradise Renal Denervation System |
| Teva Pharmaceuticals USA, INC. | $20.95 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.91 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.79 | 2023 | Horizant |
| Exeltis, USA INC. | $16.66 | 2022 | |
| Adlon Therapeutics L.P. | $15.53 | 2020 | |
| Medtronic, INC. | $14.97 | 2023 | Inpen Smart Insulin Delivery System |
| Idorsia Pharmaceuticals US INC | $13.60 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Grajcar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.